TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
Biopharma AS
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
27,420
|
23,998
|
28,170 |
| Financial expenses |
25
|
0
|
0 |
| Earnings before taxes |
5,935
|
3,701
|
923 |
| Total assets |
17,474
|
11,104
|
17,225 |
| Current assets |
17,474
|
11,104
|
17,225 |
| Current liabilities |
10,951
|
4,513
|
12,969 |
| Equity capital |
5,673
|
5,510
|
2,810 |
| - share capital |
29
|
30
|
32 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
32.5%
|
49.6%
|
16.3% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
21.6%
|
15.4%
|
3.3% |
| Return on assets (ROA) |
34.1%
|
33.3%
|
5.4% |
| Current ratio |
159.6%
|
246.0%
|
132.8% |
| Return on equity (ROE) |
104.6%
|
67.2%
|
32.8% |
| Change turnover |
3,847
|
-2,305
|
544 |
| Change turnover % |
16%
|
-9%
|
2% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.